 <h1>Migranal Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>dihydroergotamine</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about dihydroergotamine. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Migranal.</p><h2>In Summary</h2><p><b>Common side effects of Migranal include:</b> nausea and rhinitis. <b>Other side effects include:</b> application site reaction, vomiting, and altered sense of smell.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to dihydroergotamine: nasal spray</i></p><h3>Warning</h3><p class="blackboxWarning-title">Nasal route (Solution)</p><p>Serious and/or life-threatening peripheral ischemia has been associated with the coadministration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, dihydroergotamine (the active ingredient contained in Migranal) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>Check with your doctor as soon as possible if any of the following side effects occur while taking dihydroergotamine:</p><p>
<i>Less common or rare</i>
</p><ul>
<li>Chest pain</li>
<li>cough, fever, sneezing, or sore throat</li>
<li>feeling of heaviness in chest</li>
<li>irregular heartbeat</li>
<li>itching of the skin</li>
<li>numbness and tingling of face, fingers, or toes</li>
<li>pain in arms, legs, or lower back</li>
<li>pain in back, chest or left arm</li>
<li>pale bluish-colored or cold hands or feet</li>
<li>shortness of breath or troubled breathing</li>
<li>weak or absent pulses in legs</li>
</ul><p>
<i>Symptoms of overdose</i>
</p><ul>
<li>Confusion</li>
<li>convulsions (seizures)</li>
<li>delirium</li>
<li>dizziness</li>
<li> headaches</li>
<li>nausea and/or vomiting</li>
<li> numbness, tingling, and/or pain in the legs or arms</li>
<li> shortness of breath</li>
<li>stomach pain</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of dihydroergotamine may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Burning or tingling sensation, dryness, soreness, or pain in the nose</li>
<li>change in sense of taste</li>
<li>diarrhea</li>
<li>dizziness</li>
<li> dry mouth</li>
<li>fatigue</li>
<li>headache </li>
<li>increased sweating</li>
<li>nausea and or vomiting</li>
<li>muscle stiffness</li>
<li> runny and or stuffy nose</li>
<li>sudden sweatings and feelings of warmth</li>
<li>sensation of burning, warmth, or heat </li>
<li>sore throat</li>
<li>sleepiness </li>
<li>unexplained nose bleeds</li>
<li> unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>blurred vision</li>
<li>cold clammy skin</li>
<li>confusion</li>
<li>congestion in chest</li>
<li>cough</li>
<li>decreased appetite</li>
<li>depression</li>
<li>difficulty swallowing</li>
<li>dizziness or lightheadedness when getting up from a lying or sitting position</li>
<li>ear pain</li>
<li>eye pain</li>
<li> fever</li>
<li>heartburn</li>
<li>increased watering of eyes</li>
<li>increased watering of the mouth </li>
<li>increased yawning</li>
<li>muscle weakness</li>
<li>nervousness</li>
<li> pinpoint red spots on skin</li>
<li>pounding heartbeat</li>
<li>red or irritated eyes</li>
<li>ringing or buzzing in ears</li>
<li>skin rash</li>
<li>stomach pain</li>
<li>sudden fainting</li>
<li> swelling of face, fingers, feet, or lower legs</li>
<li> trembling or shaking of hands or feet</li>
<li>trouble in sleeping</li>
<li>unusual feeling of well being</li>
</ul><p>
<!-- end nasal spray --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dihydroergotamine: injectable solution, nasal spray</i></p><h3>General</h3><p>The most commonly reported adverse events have included nausea and vomiting; with use of the nasal spray, rhinitis, altered sense of taste, and application site reactions have also been reported.</p><h3>Cardiovascular</h3><p>Deaths due to cardiac events have been reported with parenteral use, but no cardiac related deaths were reported during clinical studies with the nasal spray.  Reports of serious cardiac events with the injection appear to be rare.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Edema, palpitation, tachycardia</p>
<p><b>Rare</b> (less than 0.1%): Hypotension, peripheral ischemia, angina, cardiac valvular fibrosis</p>
<p><b>Frequency not reported</b>: Acute myocardial infarction, transient myocardial ischemia, ventricular tachycardia, ventricular fibrillation, coronary artery vasospasm, bradycardia, extrasystoles, intermittent claudication, Raynaud's phenomenon</p>
<p><b>Postmarketing reports</b>: Vasospasm, hypertension, flushing, peripheral ischemia, gangrene<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, somnolence, paraesthesia</p>
<p><b>Uncommon</b> (0.1% to 1%): Tremor, hypoesthesia, altered sense of smell</p>
<p><b>Rare</b> (less than 0.1%): Speech disorder, hyperkinesia, stupor, abnormal gait, depression, aggravated migraine, convulsions</p>
<p><b>Frequency not reported</b>: Cerebral hemorrhage, subarachnoid hemorrhage, stroke, headache<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Local irritation (nasal spray; 30%) </p>
<p><b>Common</b> (1% to 10%): Application site reactions </p>
<p><b>Uncommon</b> (0.1% to 1%): Local anesthesia<sup>[Ref]</sup></p><p>Almost 30% of patients receiving the nasal spray reported irritation in the nose, throat, and/or disturbances in taste.  Symptoms of congestion, burning, dryness, paraesthesia, discharge, epistaxis, pain, and soreness, mostly mild to moderate and transient, have been reported.  In most (approximately 70%), symptoms resolved within 4 hours.  The consequence of extended and repeated use on the nasal mucosa have not been studied.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Rhinitis (nasal spray; 26%) </p>
<p><b>Common</b> (1% to 10%): Pharyngitis, sinusitis </p>
<p><b>Uncommon</b> (0.1% to 1%): Dyspnea, upper respiratory tract infections</p>
<p><b>Rare</b> (less than 0.1%): Bronchospasm, bronchitis, pleural pain, epistaxis, yawning</p>
<p><b>Postmarketing reports</b>: Pleural fibrosis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>The most frequent side effect with the use of intravenous dihydroergotamine (the active ingredient contained in Migranal) is nausea.  Following intramuscular or intranasal administration, the incidence of nausea is lower.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Nausea, vomiting, diarrhea</p>
<p><b>Uncommon</b> (0.1% to 1%): Abdominal pain, dyspepsia, hiccup, dry mouth</p>
<p><b>Rare</b> (less than 0.1%): Increased salivation, esophagospasm, anorexia</p>
<p><b>Frequency not reported</b>: Colonic ischemia</p>
<p><b>Postmarketing reports</b>: Retroperitoneal fibrosis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Uncommon</b> (0.1% to 1%): Vertigo, tinnitus, earache, feeling cold, malaise, rigors, fever, fatigue, asthenia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Stiffness</p>
<p><b>Uncommon</b> (0.1% to 1%): Cramps, myalgia, muscular weakness, dystonia</p>
<p>Rare (Less than 0.1%): Arthralgia, involuntary muscle contractions, rigidity</p>
<p><b>Frequency not reported</b>: Leg pain, muscle spasms<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal artery spasm<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions such as skin rash, face edema, urticaria, and dyspnea</p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Photophobia, conjunctivitis, abnormal lacrimation, abnormal vision, periorbital edema</p>
<p><b>Rare</b> (less than 0.1%): Eye pain</p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Nervousness, euphoria, insomnia, impaired concentration</p>
<p><b>Rare</b> (less than 0.1%): Anxiety</p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Petechia, pruritus, rash, cold clammy skin</p>
<p><b>Rare</b> (less than 0.1%): Papular rash, urticaria, herpes simplex</p>
<p><b>Frequency not reported</b>: Sweating</p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Increased micturition frequency, cystitis</p>
<p><b>Rare</b> (less than 0.1%): Pelvic inflammation, vaginitis</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Robbins L, Remmes A "Outpatient repetitive intravenous dihydroergotamine." Headache 32 (1992): 455-8</p><p id="ref_2">2. "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ. </p><p id="ref_3">3. Malaquin F, Urban T, Ostinelli J, Ghedira H, Lacronique J "Pleural and retroperitoneal fibrosis from dihydroergotamine ." N Engl J Med 321 (1989): 1760</p><p id="ref_4">4. Schulman EA, Rosenberg SB "Claudication: an unusual side effect of DHE administration." Headache 31 (1991): 237-9</p><p id="ref_5">5. "Drugs for migraine." Med Lett Drugs Ther 37 (1995): 17-20</p><p id="ref_6">6. Backonja M, Beinlich B, Dulli D, Schutta HS "Haloperidol and lorazepam for the treatment of nausea and vomiting associated with the treatment of intractable migraine headaches ." Arch Neurol 46 (1989): 724</p><p id="ref_7">7. Lipton RB "Ergotamine tartrate and dihydroergotamine mesylate: safety profiles." Headache 37 Suppl (1997): s33-41</p><p id="ref_8">8. Henry PY, Larre P, Aupy M, Lafforgue JL, Orgogozo JM "Reversible cerebral arteriopathy associated with the administration of ergot derivatives." Cephalalgia 4 (1984): 171-8</p><p id="ref_9">9. Bachner EJ, Konsens RM, Priem L, King T, Froimson AI "Reversible vasospasm in association with the use of heparin and dihydroergotamine." Clin Orthop No. 283 (1992): 261-4</p><p id="ref_10">10. Mattsson E, Ohlin A, Balkfors B, Fredin HO, Nilsson P, Bergqvist D "Lower-limb vasospasm and renal failure during postoperative thromboprophylaxis. Case report." Eur J Surg 157 (1991): 289-92</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Migranal (dihydroergotamine)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>22 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: antimigraine agents</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Migranal &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>D.H.E. 45</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Cluster Headaches</li>
<li>Migraine</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to dihydroergotamine: injectable solution, nasal spray</i></p><h3>General</h3><p>The most commonly reported adverse events have included nausea and vomiting; with use of the nasal spray, rhinitis, altered sense of taste, and application site reactions have also been reported.</p><h3>Cardiovascular</h3><p>Deaths due to cardiac events have been reported with parenteral use, but no cardiac related deaths were reported during clinical studies with the nasal spray.  Reports of serious cardiac events with the injection appear to be rare.<sup>[Ref]</sup></p><p><b>Uncommon</b> (0.1% to 1%): Edema, palpitation, tachycardia</p><p><b>Rare</b> (less than 0.1%): Hypotension, peripheral ischemia, angina, cardiac valvular fibrosis</p><p><b>Frequency not reported</b>: Acute myocardial infarction, transient myocardial ischemia, ventricular tachycardia, ventricular fibrillation, coronary artery vasospasm, bradycardia, extrasystoles, intermittent claudication, Raynaud's phenomenon</p><p><b>Postmarketing reports</b>: Vasospasm, hypertension, flushing, peripheral ischemia, gangrene<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Dizziness, somnolence, paraesthesia</p><p><b>Uncommon</b> (0.1% to 1%): Tremor, hypoesthesia, altered sense of smell</p><p><b>Rare</b> (less than 0.1%): Speech disorder, hyperkinesia, stupor, abnormal gait, depression, aggravated migraine, convulsions</p><p><b>Frequency not reported</b>: Cerebral hemorrhage, subarachnoid hemorrhage, stroke, headache<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Local irritation (nasal spray; 30%) </p><p><b>Common</b> (1% to 10%): Application site reactions </p><p><b>Uncommon</b> (0.1% to 1%): Local anesthesia<sup>[Ref]</sup></p><p>Almost 30% of patients receiving the nasal spray reported irritation in the nose, throat, and/or disturbances in taste.  Symptoms of congestion, burning, dryness, paraesthesia, discharge, epistaxis, pain, and soreness, mostly mild to moderate and transient, have been reported.  In most (approximately 70%), symptoms resolved within 4 hours.  The consequence of extended and repeated use on the nasal mucosa have not been studied.<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Rhinitis (nasal spray; 26%) </p><p><b>Common</b> (1% to 10%): Pharyngitis, sinusitis </p><p><b>Uncommon</b> (0.1% to 1%): Dyspnea, upper respiratory tract infections</p><p><b>Rare</b> (less than 0.1%): Bronchospasm, bronchitis, pleural pain, epistaxis, yawning</p><p><b>Postmarketing reports</b>: Pleural fibrosis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>The most frequent side effect with the use of intravenous dihydroergotamine (the active ingredient contained in Migranal) is nausea.  Following intramuscular or intranasal administration, the incidence of nausea is lower.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Nausea, vomiting, diarrhea</p><p><b>Uncommon</b> (0.1% to 1%): Abdominal pain, dyspepsia, hiccup, dry mouth</p><p><b>Rare</b> (less than 0.1%): Increased salivation, esophagospasm, anorexia</p><p><b>Frequency not reported</b>: Colonic ischemia</p><p><b>Postmarketing reports</b>: Retroperitoneal fibrosis<sup>[Ref]</sup></p><h3>Other</h3><p><b>Uncommon</b> (0.1% to 1%): Vertigo, tinnitus, earache, feeling cold, malaise, rigors, fever, fatigue, asthenia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Stiffness</p><p><b>Uncommon</b> (0.1% to 1%): Cramps, myalgia, muscular weakness, dystonia</p><p>Rare (Less than 0.1%): Arthralgia, involuntary muscle contractions, rigidity</p><p><b>Frequency not reported</b>: Leg pain, muscle spasms<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Renal artery spasm<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions such as skin rash, face edema, urticaria, and dyspnea</p><h3>Ocular</h3><p><b>Uncommon</b> (0.1% to 1%): Photophobia, conjunctivitis, abnormal lacrimation, abnormal vision, periorbital edema</p><p><b>Rare</b> (less than 0.1%): Eye pain</p><h3>Psychiatric</h3><p><b>Uncommon</b> (0.1% to 1%): Nervousness, euphoria, insomnia, impaired concentration</p><p><b>Rare</b> (less than 0.1%): Anxiety</p><h3>Dermatologic</h3><p><b>Uncommon</b> (0.1% to 1%): Petechia, pruritus, rash, cold clammy skin</p><p><b>Rare</b> (less than 0.1%): Papular rash, urticaria, herpes simplex</p><p><b>Frequency not reported</b>: Sweating</p><h3>Genitourinary</h3><p><b>Uncommon</b> (0.1% to 1%): Increased micturition frequency, cystitis</p><p><b>Rare</b> (less than 0.1%): Pelvic inflammation, vaginitis</p><p id="ref_1">1. Robbins L, Remmes A "Outpatient repetitive intravenous dihydroergotamine." Headache 32 (1992): 455-8</p><p id="ref_2">2. "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ. </p><p id="ref_3">3. Malaquin F, Urban T, Ostinelli J, Ghedira H, Lacronique J "Pleural and retroperitoneal fibrosis from dihydroergotamine ." N Engl J Med 321 (1989): 1760</p><p id="ref_4">4. Schulman EA, Rosenberg SB "Claudication: an unusual side effect of DHE administration." Headache 31 (1991): 237-9</p><p id="ref_5">5. "Drugs for migraine." Med Lett Drugs Ther 37 (1995): 17-20</p><p id="ref_6">6. Backonja M, Beinlich B, Dulli D, Schutta HS "Haloperidol and lorazepam for the treatment of nausea and vomiting associated with the treatment of intractable migraine headaches ." Arch Neurol 46 (1989): 724</p><p id="ref_7">7. Lipton RB "Ergotamine tartrate and dihydroergotamine mesylate: safety profiles." Headache 37 Suppl (1997): s33-41</p><p id="ref_8">8. Henry PY, Larre P, Aupy M, Lafforgue JL, Orgogozo JM "Reversible cerebral arteriopathy associated with the administration of ergot derivatives." Cephalalgia 4 (1984): 171-8</p><p id="ref_9">9. Bachner EJ, Konsens RM, Priem L, King T, Froimson AI "Reversible vasospasm in association with the use of heparin and dihydroergotamine." Clin Orthop No. 283 (1992): 261-4</p><p id="ref_10">10. Mattsson E, Ohlin A, Balkfors B, Fredin HO, Nilsson P, Bergqvist D "Lower-limb vasospasm and renal failure during postoperative thromboprophylaxis. Case report." Eur J Surg 157 (1991): 289-92</p><h2>More about Migranal (dihydroergotamine)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>22 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: antimigraine agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Migranal &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Cluster Headaches</li>
<li>Migraine</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>